These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38126466)

  • 1. [COVID-19 vaccination at the University of Alicante (Spain): detection of neutralizing antibodies against SARS-CoV-2 by rapid serological test, a cross-sectional study].
    Montagud AC; Vicente-Alcalde N; Gabaldón-Bravo EM; Hurtado-Sánchez JA; Montagud E; Egoavil CM; Chavarría-Alarcón E; Caballero P; Tuells J
    Rev Esp Salud Publica; 2023 Dec; 97():. PubMed ID: 38126466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine.
    Montagud AC; Llenas-García J; Moragues R; Pérez-Bernabeu A; Alcocer Pertegal MJ; García Gómez FJ; Gamayo Serna AM; García Morante H; Caballero P; Tuells J
    Rev Clin Esp (Barc); 2024 Apr; 224(4):197-203. PubMed ID: 38423384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity.
    Faizo AA; Qashqari FS; El-Kafrawy SA; Barasheed O; Almashjary MN; Alfelali M; Bawazir AA; Albarakati BM; Khayyat SA; Hassan AM; Alandijany TA; Azhar EI
    J Med Virol; 2023 Jan; 95(1):e28130. PubMed ID: 36068377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France.
    Decarreaux D; Pouquet M; Souty C; Vilcu AM; Prévot-Monsacre P; Fourié T; Villarroel PMS; Priet S; Blanché H; Sebaoun JM; Deleuze JF; Turbelin C; Werner A; Kochert F; Grosgogeat B; Rabiega P; Laupie J; Abraham N; Guerrisi C; Noël H; Van der Werf S; Carrat F; Hanslik T; Charrel R; De Lamballerie X; Blanchon T; Falchi A
    Viruses; 2022 May; 14(5):. PubMed ID: 35632699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
    Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
    Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.
    Mallah N; Pardo-Seco J; Ares-Gómez S; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
    Pediatr Allergy Immunol; 2023 Oct; 34(10):e14037. PubMed ID: 37877845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients.
    Tolan NV; Sherman AC; Zhou G; Nabel KG; Desjardins M; Melanson S; Kanjilal S; Moheed S; Kupelian J; Kaufman RM; Ryan ET; LaRocque RC; Branda JA; Dighe AS; Abraham J; Baden LR; Charles RC; Turbett SE
    Microbiol Spectr; 2022 Apr; 10(2):e0021122. PubMed ID: 35311584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of SARS-CoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco).
    Ben Houmich T; Tali A; Debbagh F; Lamrani Hanchi A; Soraa N
    Int J Immunopathol Pharmacol; 2022; 36():3946320221133697. PubMed ID: 36215392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies.
    Wüsthoff LEC; Lund-Johansen F; Henriksen K; Wildendahl G; Jacobsen JA; Gomes L; Anjum HS; Barlinn R; Kran AB; Munthe LA; Vaage JT
    Harm Reduct J; 2024 Jun; 21(1):120. PubMed ID: 38890611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
    Hayer J; Urlaub E
    Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland.
    Brown AC; Koshute PT; Cowley HP; Robinette MS; Gravelyn SR; Patel SV; Ju EY; Frommer CT; Zambidis AE; Schneider EJ; Zhao MY; Mugo BK; Clarke W; Kruczynski K; Pisanic N; Heaney CD; Colella TA
    Microbiol Spectr; 2023 Aug; 11(4):e0276522. PubMed ID: 37289070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
    Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
    EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.